MedaSorb Technologies raises $1.3 million to help finance ongoing European Sepsis Trial

Download PDF Copy

Editorial Checklist

Reviewed

Oct 9 2009MedaSorb Technologies Corporation

MedaSorb Technologies Corporation (OTCBB: MSBT) and its wholly-owned subsidiary CytoSorbents, Inc., announced that it has raised $1.3 million in the exercise of the warrant attached to the Series B financing completed in August 2008. Dr. Phillip Chan, Chief Executive Officer, stated, "We are pleased to have the continued support of our existing investors. These funds help provide additional runway to finance our ongoing European Sepsis Trial and the CE Mark application process."

Additional information regarding the warrant exercise can be viewed in the Company's 8-K filed with the SEC on October 9, 2009, which is available at http://www.sec.gov.

Source:

MedaSorb Technologies Corporation

Posted in:

Tags: Cancer, Chemotherapy, Cytokines, Dialysis, Exercise, Influenza, Pneumonia, Sepsis, Trauma

Comments (0)

Download PDF Copy

Suggested Reading

Research sheds light on post-sepsis immune suppression mechanism

Research sheds light on post-sepsis immune suppression mechanism

AI in healthcare shows promise in trials but needs real-world testing to ensure effectiveness

AI in healthcare shows promise in trials but needs real-world testing to ensure effectiveness

Updated pediatric sepsis definition could save countless children's lives

Updated pediatric sepsis definition could save countless children's lives

New method predicts sepsis and organ failure in children

New method predicts sepsis and organ failure in children

AI model identifies sepsis patients before symptoms appear

AI model identifies sepsis patients before symptoms appear

Deep learning model COMPOSER enhances early sepsis detection and patient survival

Deep learning model COMPOSER enhances early sepsis detection and patient survival

Study links pneumonia transmission in seniors to contact with young children

Study links pneumonia transmission in seniors to contact with young children

Oral azithromycin reduces maternal sepsis and healthcare costs in low-resource settings

Oral azithromycin reduces maternal sepsis and healthcare costs in low-resource settings

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Circulatory cholesterol levels are inversely linked to mortality of patients with sepsis and critical illness